CP-751,871 and Erlotinib Combination Explored for Overall Survival Benefit in Refractory Non-Small Cell Lung Cancer
Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer
Abstract
A clinical trial investigated adding CP-751,871 to erlotinib therapy to improve overall survival in patients with advanced, refractory non-adenocarcinoma NSCLC.